Personalized tumor therapy with 3D cell culture and high-throughput flow cytometry
CompanyCELLphenomics, Berlin, Germany
CELLphenomics has developed a functional precision medicine platform that combines high-throughput flow cytometry with advanced automation and an optimized analysis pipeline.
CELLphenomics' ex vivo assays combine machine learning, automation and high-throughput flow cytometry to predict response to potentially approved or investigational therapies and ultimately determine which drugs or drug combinations are most effective for specific cancer types. To do this, PD3D® cell cultures or tumor organoids are grown from tumor biopsies within a short period of time. These are then treated in parallel with all possible cancer drugs and combinations of drugs. Classical chemotherapeutic agents as well as small molecules and therapeutic antibodies are tested individually or in combination. In addition, proteomic analysis can be performed.
CELLphenomics combines data generated by its flow cytometry platform with valuable patient clinical characteristics for patient stratification, enabling more precise treatment of patients with solid cancers. CELLphenomics uses cutting-edge cancer research technology to advance new therapies from target identification in drug discovery to clinical trial validation and successful clinical development.
info@cellphenomics.com
Added on: 07-30-2021
[1] https://www.cellphenomics.com/
